Director Dealings

RNS Number : 5208I

Ergomed plc

05 December 2022

 

Director Dealing

Guildford, UK - 5 December 2022 : Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that on 2 December 2022, Richard Barfield, Chief Financial Officer of Ergomed, exercised options under the Company's Long Term Incentive Plan and sold the shares issued by the Company pursuant to such exercise. Mr Barfield exercised options over 125,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at an exercise price of £0.01 per share and subsequently sold 125,000 Ordinary Shares at a price of 13.45 per share.

Following this sale, Richard Barfield holds 25,000 Ordinary Shares representing 0.05% of the Company's issued share capital.

The notification set out below is provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Richard Barfield
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ergomed plc
b)	Legal Entity Identifier	213800BVS8I9VMC1AP84
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each  GB00BN7ZCY67
b)	Nature of the transaction	Exercise of share options under the Company's Long Term Incentive Plan
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		Exercise price £0.01	125,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	n/a
f)	Date of the transaction	2 December 2022
g)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Richard Barfield
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ergomed plc
b)	Legal Entity Identifier	213800BVS8I9VMC1AP84
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each  GB00BN7ZCY67
b)	Nature of the transaction	Sale
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		£13.45	125,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	125,000 £13.45 £1,681,250
f)	Date of the transaction	2 December 2022
g)	Place of the transaction	London Stock Exchange, AIM

ENDS

Enquiries :

Ergomed plc     Tel: [phone]

Dr Miroslav Reljanović (Executive Chairman) 

Richard Barfield (Chief Financial Officer) 

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis      Tel: [phone]

Freddie Barnfield / Euan Brown (Nominated Adviser) 

James Black (Broker) 

Peel Hunt LLP    Tel: [phone]

James Steel / Dr Christopher Golden

Consilium Strategic Communications   Tel: [phone]

Chris Gardner / Matthew Neal   [e-mail]

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

 

END

 

 

DSHUPGPPPUPPGBC